Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-3,017
Closed -$689K 277
2025
Q4
$689K Sell
3,017
-1,480
-33% -$337K 0.18% 159
2025
Q3
$1.04M Buy
4,497
+1,610
+56% +$328K 0.27% 102
2025
Q2
$536K Buy
+2,887
New +$537K 0.14% 173
2024
Q4
Sell
-4,125
Closed -$815K 200
2024
Q3
$815K Buy
+4,125
New +$770K 0.2% 116
2024
Q2
Sell
-8,952
Closed -$1.63M 165
2024
Q1
$1.63M Sell
8,952
-2,006
-18% -$346K 0.34% 77
2023
Q4
$1.7M Buy
+10,958
New +$1.6M 0.34% 76
2023
Q2
Sell
-9,897
Closed -$1.58M 185
2023
Q1
$1.58M Sell
9,897
-34,119
-78% -$5.22M 0.32% 86
2022
Q4
$7.11M Buy
+44,016
New +$6.75M 1.52% 13
2022
Q3
Sell
-51,285
Closed -$7.63M 110
2022
Q2
$7.63M Sell
51,285
-7,698
-13% -$1.18M 1.65% 17
2022
Q1
$9.33M Sell
58,983
-55,583
-49% -$8.07M 1.51% 12
2021
Q4
$15.3M Buy
114,566
+84,439
+280% +$9.97M 2.45% 10
2021
Q3
$3.17M Sell
30,127
-29,969
-50% -$3.42M 0.53% 48
2021
Q2
$6.77M Sell
60,096
-45,310
-43% -$5.1M 1.04% 22
2021
Q1
$11.4M Buy
105,406
+85,767
+437% +$9.17M 1.79% 10
2020
Q4
$2.1M Sell
19,639
-1,979
-9% -$190K 0.32% 67
2020
Q3
$1.89M Buy
21,618
+178
+0.8% +$16.8K 0.29% 59
2020
Q2
$2.1M Buy
+21,440
New +$1.89M 0.34% 42
2020
Q1
Sell
-150,512
Closed -$13.3M 85
2019
Q4
$13.3M Sell
150,512
-3,145
-2% -$261K 1.42% 13
2019
Q3
$11.6M Buy
153,657
+83,909
+120% +$5.75M 1.1% 17
2019
Q2
$5.07M Buy
+69,748
New +$5.48M 0.45% 44
2018
Q1
Sell
-87,746
Closed -$8.49M 183
2017
Q4
$8.49M Buy
+87,746
New +$8.27M 0.39% 57
2017
Q3
Sell
-205,733
Closed -$14.9M 276
2017
Q2
$14.9M Sell
205,733
-51,016
-20% -$3.43M 0.65% 32
2017
Q1
$16.7M Buy
256,749
+251,359
+4,663% +$15.8M 0.74% 37
2016
Q4
$338K Sell
5,390
-15,540
-74% -$949K 0.01% 256
2016
Q3
$1.32M Buy
+20,930
New +$1.35M 0.05% 192
2015
Q3
Sell
-1,553,085
Closed -$104M 148
2015
Q2
$104M Buy
1,553,085
+109,214
+8% +$7.13M 2.63% 8
2015
Q1
$84.5M Buy
+1,443,871
New +$87.2M 2% 14

Other funds holding ABBV

WBI Investments's ABBV Position: Q1 2026 in Review

WBI Investments sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 3,017 shares — an estimated $689K sold.

WBI Investments first reported a position in ABBV in Q1 2015 and held it in 27 quarters. The position peaked at $104M in Q2 2015. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • WBI Investments reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • WBI Investments sold 3,017 AbbVie shares in Q1 2026, an estimated $689K.
  • WBI Investments first reported a position in AbbVie in Q1 2015 and held it in 27 quarters.
  • WBI Investments's AbbVie position peaked at $104M in Q2 2015.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on WBI Investments's 13F filing for Q1 2026, filed 11 May 2026.